Screener
Veradermics MANE G&A
G&A at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Veradermics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 5:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001827635-26-000019
| (in thousands, except share and per share amounts) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $20,925 | $11,447 |
| General and administrative | 8,937 | 1,468 |
| Total operating expenses | 29,862 | 12,915 |
| Loss from operations | (29,862) | (12,915) |
| Other income: | ||
| Interest income | 2,481 | 482 |
| Other income | 149 | 33 |
Item 1. Condensed Consolidated Financial Statements (
FAQ
- What is Veradermics's G&A?
- Veradermics (MANE) reported G&A of $8.94M in Q1 2026.
- How has Veradermics's G&A changed year-over-year?
- Veradermics's G&A increased by 508.8% year-over-year, from $1.47M to $8.94M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Veradermics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude